ML18037A308

Northwest Medical Isotopes, LLC - Transmittal Letter Regarding Issuance of Construction Permit for a Medical Radioisotope Production Facility

ML18037A308
Person / Time
Site:	Northwest Medical Isotopes
Issue date:	05/09/2018
From:	Lund A Research and Test Reactors Licensing Projects Branch
To:	Haass C Northwest Medical Isotopes
Balazik M, 415-2856
Shared Package
ML18038B141	List: ML18037A308 ML18038B133 NRC-2013-0235, Federal Register Notice - Northwest Medical Isotopes, LLC Construction Permit
References
Download: ML18037A308 (2)

Text

May 9, 2018 Carolyn Haass, Chief Operating Officer Northwest Medical Isotopes, LLC 815 Northwest 9th Street, Suite 256 Corvallis, OR 97330

SUBJECT:

NORTHWEST MEDICAL ISOTOPES, LLC - ISSUANCE OF CONSTRUCTION PERMIT FOR MEDICAL RADIOISOTOPE PRODUCTION FACILITY

Dear Ms. Haass:

The U.S. Nuclear Regulatory Commission (NRC or the Commission) is issuing Construction Permit No. CPMIF-002 to Northwest Medical Isotopes, LLC (NWMI), pursuant to Title 10 of the Code of Federal Regulations (10 CFR) Section 50.35, Issuance of construction permits. This construction permit, which is immediately effective, authorizes NWMI to construct the proposed 10 CFR Part 50 production facility designed for the production of medical radioisotopes in Columbia, Missouri, as described in NWMIs application for a construction permit and in evidence received at the public hearing held by the Commission on January 23, 2018. This permit was issued after the issuance of the Advisory Committee on Reactor Safeguards letter to the Commission, dated November 6, 2017 (Agencywide Documents Access and Management System (ADAMS) Accession No. ML17310B511), and as authorized by the Commissions Memorandum and Order, CLI-18-06, dated May 3, 2018 (ADAMS Accession No. ML18123A374).

Enclosed is a copy of CPMIF-002, including the Environmental Protection Plan (Appendix A), for the NWMI medical radioisotope production facility. Also enclosed is a summary record of decision. A related notice will be forwarded to the Office of the Federal Register for publication.

If you have questions regarding CPMIF-002, please contact Mr. Michael Balazik at 301-415-2856, or by electronic mail at Michael.Balazik@nrc.gov.

Sincerely,

/RA/

A. Louise Lund, Director Division of Licensing Projects Office of Nuclear Reactor Regulation Docket No. 50-609

Enclosures:

As stated

Package ML18038B141 Letter ML18037A308 FRN ML18038B133 Construction Permit ML18037A468 *concurrence via e-mail NRC-001 OFFICE NRR/DLP/PRLB/PM NRR/DLP/PRLB/LA* OGC - NLO NAME MBalazik NParker MYoung DATE 05/03/2018 02/16/2018 05/07/2018 OFFICE NRR/DLP/PRLB/ABC NRR/DLP/D NAME SLynch LLund DATE 05/03/2018 05/09/2018 May 9, 2018 Carolyn Haass, Chief Operating Officer Northwest Medical Isotopes, LLC 815 Northwest 9th Street, Suite 256 Corvallis, OR 97330

SUBJECT:

NORTHWEST MEDICAL ISOTOPES, LLC - ISSUANCE OF CONSTRUCTION PERMIT FOR MEDICAL RADIOISOTOPE PRODUCTION FACILITY

Dear Ms. Haass:

The U.S. Nuclear Regulatory Commission (NRC or the Commission) is issuing Construction Permit No. CPMIF-002 to Northwest Medical Isotopes, LLC (NWMI), pursuant to Title 10 of the Code of Federal Regulations (10 CFR) Section 50.35, Issuance of construction permits. This construction permit, which is immediately effective, authorizes NWMI to construct the proposed 10 CFR Part 50 production facility designed for the production of medical radioisotopes in Columbia, Missouri, as described in NWMIs application for a construction permit and in evidence received at the public hearing held by the Commission on January 23, 2018. This permit was issued after the issuance of the Advisory Committee on Reactor Safeguards letter to the Commission, dated November 6, 2017 (Agencywide Documents Access and Management System (ADAMS) Accession No. ML17310B511), and as authorized by the Commissions Memorandum and Order, CLI-18-06, dated May 3, 2018 (ADAMS Accession No. ML18123A374).

Enclosed is a copy of CPMIF-002, including the Environmental Protection Plan (Appendix A), for the NWMI medical radioisotope production facility. Also enclosed is a summary record of decision. A related notice will be forwarded to the Office of the Federal Register for publication.

If you have questions regarding CPMIF-002, please contact Mr. Michael Balazik at 301-415-2856, or by electronic mail at Michael.Balazik@nrc.gov.

Sincerely,

/RA/

A. Louise Lund, Director Division of Licensing Projects Office of Nuclear Reactor Regulation Docket No. 50-609

Enclosures:

As stated

Package ML18038B141 Letter ML18037A308 FRN ML18038B133 Construction Permit ML18037A468 *concurrence via e-mail NRC-001 OFFICE NRR/DLP/PRLB/PM NRR/DLP/PRLB/LA* OGC - NLO NAME MBalazik NParker MYoung DATE 05/03/2018 02/16/2018 05/07/2018 OFFICE NRR/DLP/PRLB/ABC NRR/DLP/D NAME SLynch LLund DATE 05/03/2018 05/09/2018